Mechanism-informed development of EphA2 PET imaging for noninvasive target assessment in triple-negative breast cancer
Year: 2026
Type: article
Abstract: Triple-negative breast cancer (TNBC) exhibits marked spatial heterogeneity and variable sensitivity to immune checkpoint blockade, creating a need for whole-body biomarkers of immune-relevant tumor states. Here, tumor-cell EphA2 is identified as implicated in an immune-restricted TNBC phenotype. Human transcriptomic and spatial analyses, together with immunocompetent tumor models, show that EphA2 is associated with aggressive malignant-cell states, reduced CD8 + T-cell infiltration and effector function, and limited responsiveness to PD-1 blockade. Mechanistic analyses linked EphA2 to a CD73-related AMP-to-adenosine program accompanied by coordinated changes in AKT/mTOR–HIF-1α signaling, whereas CD73 re-expression attenuated several tumor and immune phenotypes associated with Epha2 knockdown. Guided by this biology, two gallium-68-labeled EphA2-targeting bicyclic peptide radiotracers are compared through AI-assisted computational evaluation and experimental validation. The FZEAR11 precursor showed stronger measured EphA2 affinity than FZEAR12, while [ 68 Ga]Ga-FZEAR11 exhibited higher cellular and tumor uptake, rapid blood clearance, and superior tumor-to-muscle contrast relative to [ 68 Ga]Ga-FZEAR12. Blocking studies and EphA2-high versus EphA2-low models support a substantial target-associated and saturable component of tumor accumulation. Exploratory first-in-human PET/CT in three patients demonstrates same-day visualization of pathologically confirmed, EphA2-expressing TNBC lesions against a low soft-tissue background. These findings establish a mechanism-informed strategy for EphA2 PET and support further evaluation of [ 68 Ga]Ga-FZEAR11 for whole-body target assessment in TNBC.
Source: Journal of Nanobiotechnology
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W7233584850
